epoetin alfa
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Blood Transfusion
Conditions
Blood Transfusion, Orthopedic Procedures, Anemia
Trial Timeline
Apr 1, 1991 → Oct 1, 1991
NCT ID
NCT00270036About epoetin alfa
epoetin alfa is a phase 2 stage product being developed by Johnson & Johnson for Blood Transfusion. The current trial status is completed. This product is registered under clinical trial identifier NCT00270036. Target conditions include Blood Transfusion, Orthopedic Procedures, Anemia.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00270010 | Phase 2 | Completed |
| NCT00266617 | Phase 2 | Completed |
| NCT00002022 | Pre-clinical | Completed |
| NCT00269984 | Phase 2 | Completed |
| NCT00269945 | Phase 2 | Completed |
| NCT00270114 | Phase 2/3 | Completed |
| NCT00446602 | Phase 2 | Withdrawn |
| NCT00270179 | Phase 3 | Completed |
| NCT00269997 | Phase 2 | Completed |
| NCT00270023 | Phase 2/3 | Completed |
| NCT00270270 | Phase 2 | Completed |
| NCT00337935 | Phase 2 | Completed |
| NCT00306267 | Phase 2 | Terminated |
| NCT00641589 | Phase 1 | Completed |
| NCT00246298 | Phase 2 | Terminated |
| NCT00212875 | Phase 2 | Completed |
| NCT00236405 | Phase 2 | Terminated |
| NCT00240734 | Phase 2 | Terminated |
| NCT00210587 | Phase 3 | Completed |
| NCT00236678 | Phase 2 | Terminated |
Competing Products
20 competing products in Blood Transfusion
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| micafungin + voriconazole | Astellas Pharma | Approved | 85 |
| Cefiderocol | Shionogi | Phase 2 | 52 |
| Bunazosin + Doxazosin + Valsartin | Eisai | Approved | 85 |
| Pegfilgrastim | Kyowa Kirin | Phase 2 | 52 |
| epoetin alfa | Johnson & Johnson | Phase 2/3 | 65 |
| epoetin alfa | Johnson & Johnson | Phase 2/3 | 65 |
| Metoprolol Succinate + Hydrochlorothiazide | AstraZeneca | Phase 3 | 77 |
| AZD6140 + Placebo | AstraZeneca | Phase 1 | 33 |
| NKTR-118 + moxifloxacin + Placebo | AstraZeneca | Phase 1 | 33 |
| MEDI-551 | AstraZeneca | Phase 1 | 33 |
| Ecallantide + Cyklokapron(R) | Merck | Phase 2 | 52 |
| Daptomycin | Merck | Phase 2 | 52 |
| ecallantide + placebo | Merck | Phase 2 | 52 |
| MK0859 | Merck | Phase 1 | 33 |
| Ecallantide + Placebo | Merck | Phase 2 | 52 |
| HSC835 | Novartis | Phase 2 | 52 |
| Aliskiren | Novartis | Approved | 85 |
| Aliskiren and HCTZ | Novartis | Approved | 85 |
| Aliskiren + Amlodipine + Placebo Aliskiren + Placebo Amlodipine | Novartis | Phase 2 | 52 |
| Darbepoetin alfa | Amgen | Phase 1/2 | 40 |